GeneCentric Therapeutics, Inc.

United States - Research Triangle Park, NC

• 08/11/2021
• Series B
• $7,500,000

GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou’s laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine.

GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric’s second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.

GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.

Related People

Michael Milburn (Ph.D.)Founder

United States - Apex, North Carolina

Dr. Milburn received his Ph.D. in Biophysical Chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Dr. Milburn has over 25 years of experience in biopharma and diagnostic companies including over 20 years in senior management research positions. Dr. Milburn has published over 100 scientific articles on technology, genomics, research and development in the life sciences.

Specialties: life-science emerging technologies, companion diagnostics, senior management of research and commercial operations, biotech business development, drug and diagnostic discovery technologies, drug development, biomarker discovery & validation, diagnostics development, crystallography and structural biology.

LinkedIn https://www.linkedin.com/in/michael-milburn-ph-d-8a32973/